GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » PB Ratio

MiMedx Group (MiMedx Group) PB Ratio : 7.48 (As of May. 14, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), MiMedx Group's share price is $7.90. MiMedx Group's Book Value per Share for the quarter that ended in Mar. 2024 was $1.06. Hence, MiMedx Group's PB Ratio of today is 7.48.

The historical rank and industry rank for MiMedx Group's PB Ratio or its related term are showing as below:

MDXG' s PB Ratio Range Over the Past 10 Years
Min: 4.51   Med: 11.45   Max: 6040
Current: 7.45

During the past 13 years, MiMedx Group's highest PB Ratio was 6040.00. The lowest was 4.51. And the median was 11.45.

MDXG's PB Ratio is ranked worse than
84.39% of 1313 companies
in the Biotechnology industry
Industry Median: 2.48 vs MDXG: 7.45

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MiMedx Group was 284.90% per year. The lowest was -87.00% per year. And the median was 19.80% per year.

Back to Basics: PB Ratio


MiMedx Group PB Ratio Historical Data

The historical data trend for MiMedx Group's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group PB Ratio Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.45 - 6,040.00 - 8.99

MiMedx Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 662.73 8.99 7.29

Competitive Comparison of MiMedx Group's PB Ratio

For the Biotechnology subindustry, MiMedx Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's PB Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's PB Ratio falls into.



MiMedx Group PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

MiMedx Group's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=7.90/1.056
=7.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


MiMedx Group  (NAS:MDXG) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


MiMedx Group PB Ratio Related Terms

Thank you for viewing the detailed overview of MiMedx Group's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604